Mean platelet volume on admission improves risk prediction in patients with acute coronary syndromes

Area of Science:

• Cardiology
• Clinical Risk Prediction
• Biomarkers in Cardiovascular Disease

Background:

• Acute coronary syndrome (ACS) requires accurate risk stratification for optimal patient management.
• The Global Registry of Acute Coronary Events (GRACE) score is a widely used tool for predicting ACS outcomes.
• Mean platelet volume (MPV) has emerged as a potential biomarker in cardiovascular disease.

Purpose of the Study:

• To assess the added predictive value of mean platelet volume (MPV) to the existing GRACE risk score.
• To determine if MPV can improve the risk classification of patients diagnosed with acute coronary syndrome (ACS).

Main Methods:

• Prospective evaluation of 509 consecutive patients with acute coronary syndrome (ACS).
• Measurement of mean platelet volume (MPV) and GRACE risk score upon admission.
• Utilized Cox multivariate analysis to identify independent predictors of a combined endpoint (6-month mortality or nonfatal myocardial infarction).

Main Results:

• Elevated mean platelet volume (MPV) was identified as an independent predictor of 6-month mortality or myocardial infarction (MI) in ACS patients.
• Incorporating MPV into the GRACE risk score significantly enhanced the model's global fit and discriminatory capacity.
• The revised GRACE model, including MPV, led to the accurate reclassification of 16% of the study cohort.

Conclusions:

• The addition of mean platelet volume (MPV) to the GRACE risk score offers incremental predictive value in acute coronary syndrome (ACS).
• Integrating MPV into risk assessment tools can refine the stratification of ACS patients, potentially improving clinical decision-making.
• This study supports the utility of MPV as a valuable biomarker for enhanced cardiovascular risk assessment.